X4 Pharmaceuticals Inc 4WHIM Phase 3 Clinical Trial Update Call Transcript
Good afternoon and welcome to the X4 Pharmaceuticals webinar. (Operator Instructions)
It is now my pleasure to introduce our host for the event, Dr. Paula Ragan, Founder, President, and Chief Executive Officer of X4 Pharmaceuticals.
Thank you, and thanks to all of you for joining us today to review and discuss the exciting data from our Phase 3 trial of mavorixafor in WHIM syndrome.
Before we begin, I'd like to remind everyone that on today's call, we will be making forward-looking statements regarding our regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent forms 10-K and 10-Q, both on file with the SEC.
We will begin today's program with a brief overview of our lead investigational candidate, mavorixafor, and its potential to address the many unmet needs of individuals with WHIM syndrome and our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |